What's in Rebecca Price's pipeline?

Rebecca Price has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Rebecca Price's portfolio?

Top competitors by shared drug class: The University of Hong Kong, Unity Health Toronto, University Tunis El Manar.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/rebecca-price.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Rebecca Price — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rebecca Price pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Intravenous Ketamine	Intravenous Ketamine	marketed	Dissociative anesthetic	NMDA receptors	Neuroscience

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

The University of Hong Kong · 1 shared drug class
Unity Health Toronto · 1 shared drug class
University Tunis El Manar · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Rebecca Price:

Cite this brief

Drug Landscape (2026). Rebecca Price — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rebecca-price. Accessed 2026-05-16.